(Q30978892)

27 June 2017

title

The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes (English)

1 reference

27 June 2017

1 reference

13

Kevin B Weiss

1 reference

27 June 2017

3

Michael S Blaiss

1 reference

27 June 2017

9

Stuart W Stoloff

1 reference

27 June 2017

William E Berger

1

1 reference

27 June 2017

Antonio P Legorreta

2

1 reference

27 June 2017

Eric C Schneider

4

1 reference

27 June 2017

Allan T Luskin

5

1 reference

27 June 2017

David A Stempel

6

1 reference

27 June 2017

Samy Suissa

7

1 reference

27 June 2017

David C Goodman

8

1 reference

27 June 2017

Jean A Chapman

10

1 reference

27 June 2017

Sean D Sullivan

11

1 reference

27 June 2017

Bill Vollmer

12

1 reference

27 June 2017

publication date

1 December 2004

1 reference

Annals of Allergy, Asthma & Immunology

27 June 2017

published in

1 reference

27 June 2017

volume

93

1 reference

27 June 2017

issue

6

1 reference

27 June 2017

page(s)

538-545

1 reference

Trends in the cost of illness for asthma in the United States, 1985-1994

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Compliance with national asthma management guidelines and specialty care: a health maintenance organization experience

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Outcomes of a population-based asthma management program: quality of life, absenteeism, and utilization

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Compliance with US asthma management guidelines and specialty care: a regional variation or national concern?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Preventive pharmacologic therapy among asthmatics: five years after publication of guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Toward the development of uniform reporting standards for managed care organizations: the Health Plan Employer Data and Information Set (Version 2.0).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

A quality-driven physician compensation model: four-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

National quality monitoring of Medicare health plans: the relationship between enrollees' reports and the quality of clinical care

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Do HEDIS measures reflect cost-effective practices?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Assessing quality of care via HEDIS 3.0. Is there a better way?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Low-dose inhaled corticosteroids and the prevention of death from asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in prevalence of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

Asthma variability in patients previously treated with beta2-agonists alone

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961260-4

7 January 2021

10.1016/S1081-1206(10)61260-4

Identifiers

DOI

1 reference

27 June 2017

1 reference